Literature DB >> 11429115

Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study.

E Delgado1, M León-Ponte, M L Villahermosa, M T Cuevas, L Deibis, G Echeverría, M M Thomson, L Pérez-Alvarez, S Osmanov, R Nájera.   

Abstract

We report the first study on prevalence of antiretroviral drug-associated resistance mutations in Venezuela. Protease and reverse transcriptase (RT) coding regions were analyzed in DNA samples obtained from 100 HIV-1-infected individuals. Primary resistance mutations to RT inhibitors were identified in 26% of patients treated with these drugs. Transmission of HIV-1-resistant strains was detected in a drug-naive patient (3%). Primary resistance mutations to protease inhibitors (PIs) were present in 9% of the 44 PI-treated patients and in 1 PI-naive individual. Phylogenetic analysis of these samples has resulted in the most extensive survey, to date, of HIV-1 genetic forms circulating in Venezuela. Ninety-nine samples clustered with subtype B, and 1 individual harbored the first B/F recombinant virus reported in Venezuela, with protease clustering with subtype F and RT with subtype B. In addition, this isolate had a new insertion (Glu-34 duplication) in the protease gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429115     DOI: 10.1089/088922201750237022

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.

Authors:  Ana T Dumans; Marcelo A Soares; Danuta Pieniazek; Marcia L Kalish; Veronique De Vroey; Kurt Hertogs; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India.

Authors:  Naresh Sachdeva; Shobha Sehgal; Sunil K Arora
Journal:  MedGenMed       Date:  2005-07-27

3.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

4.  A single early introduction of HIV-1 subtype B into Central America accounts for most current cases.

Authors:  Wendy Murillo; Nazle Veras; Mattia Prosperi; Ivette Lorenzana de Rivera; Gabriela Paz-Bailey; Sonia Morales-Miranda; Sandra I Juarez; Chunfu Yang; Joshua DeVos; José Pablo Marín; Mattias Mild; Jan Albert; Marco Salemi
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

Review 5.  Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.

Authors:  Santiago Avila-Rios; Omar Sued; Soo-Yon Rhee; Robert W Shafer; Gustavo Reyes-Teran; Giovanni Ravasi
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

6.  HIV-1 genetic diversity and antiretroviral drug resistance among individuals from Roraima state, northern Brazil.

Authors:  André de Lima Guerra Corado; Gonzalo Bello; Renato Augusto Carvalho Leão; Fabiana Granja; Felipe Gomes Naveca
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

7.  Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of India.

Authors:  Naresh Sachdeva; Shobha Sehgal; Sunil K Arora
Journal:  J Int AIDS Soc       Date:  2005-07-27       Impact factor: 5.396

8.  Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV.

Authors:  Lilian A Inocencio; Anderson A Pereira; Maria Cecilia A Sucupira; José Carlos C Fernandez; Célia P Jorge; Denise Fc Souza; Helena T Fink; Ricardo S Diaz; Irina M Becker; Theodoro A Suffert; Monica B Arruda; Olinda Macedo; Mariangela Bg Simão; Amilcar Tanuri
Journal:  J Int AIDS Soc       Date:  2009-09-18       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.